Hypericum perforatum extract (St. John's wort) for depression

Psychiatric Annals

Volumn 32, Issue 1, 2002, Pages 21-26

  Brenner, Ronald ^a,b   Bjerkenstedt, Lars ^c   Edman, Gunnar V ^d  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; CYCLOSPORIN; CYTOCHROME P450; DESOGESTREL PLUS ETHINYLESTRADIOL; DIGOXIN; DOPAMINE; FLUOXETINE; HOMOVANILLIC ACID; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INDINAVIR; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SODIUM ION; STEI 300; THEOPHYLLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; ZE 117; ZIMELDINE;

ACUTE GRAFT REJECTION; BRAIN CORTEX; CAUDATE NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; ERYTHEMA; GASTROINTESTINAL HEMORRHAGE; HIPPOCAMPUS; HUMAN; HYPERICUM PERFORATUM; HYPOTHALAMUS; HYPOTHESIS; MULTICENTER STUDY; NEUROPATHY; NONHUMAN; PHOTOTOXICITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; REVIEW; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SODIUM CELL LEVEL; SUN EXPOSURE;

EID: 0036106825     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020101-06     Document Type: Review

References (56)

1. Angst J. Major depression in 1998: are we providing optimal therapy? J Clin Psychiatry. 1999;60(suppl 6):5-9.
2. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry. 1999;60(suppl 20):9-15.
3. Panzarino PJ Jr. The costs of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry. 1998;59(suppl 20):11-14.
4. Müller WE, Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry. 1997;30(suppl):S71.
5. Vandenbogaerde A, Zanoli P, Puia G, et al. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacol Biochem Behav. 2000;65:627-633.
6. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med. 1984;50:272-274.
7. Yu PH. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry. 2000;33:60-65.
8. 2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry. 2000;33:14-18.
9. Bjerkenstedt L, Edman G, Flyckt L, Hagenfeldt L, Sedvall G, Wiesel FA. Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor: a dose response study in depressed patients. Psychopharmacology (Berl). 1985;87:253-259.
10. Aberg-Wistedt A, Alvarez M, Bertilsson L, Malmgren R, Wachtmeister H. Alaproclate an antidepressant?: a biochemical and clinical comparison with zimelidin. Acta Psychiatr Scand. 1985;71:256-268.
11. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system. Acta Physiol Scand Suppl. 1965;64:37-85.
12. Dray A, Gonye TJ, Oakley NR, Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 1976;113:45-47.
13. Laakman G, Schüle C, Baghai T, Kieser M. St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31(suppl):54-59.
14. +I. J Pharmacol Exp Ther. 1999;290:1363-1368.
15. Jager-Becker D. Neue Erkenntniss zum Wirkprinzip von Johanniskraut: Als Breibandantidepressivum effektiv und sicher. Presented at Biocenter Symposium on Drug Therapy; February 20-22, 2000; Frankfurt, Germany.
16. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of anti-depressant activity. Pharmacopsychiatry. 1997;30(suppl 2):102-107.
17. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand. 1990;81:231-235.
18. Hartvig P. Johannesörtextrakt vid behandling av mild depression. Läkemedelsvärlden. 1997;101:37-39.
19. Wagner H, Bladt S. Pharmaceutical quality of hypericum extracts. J Geriatr Psychiatry Neurol. 1994;(suppl 1):65-68.
20. Hoffmann J, Kühl ED. Therapie von depressiven Zuständen mit Hypericin. Zeitschrift fur Allgemeinmedizin. 1979;55:776-782.
21. Linde K, Ramirez G, Mulrow CD, et al. St John's Wort for depression: an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253-258.
22. Kim HL, Streltzer J, Goebert D. St. John's Wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis. 1999;187:532-538.
23. Stevinson C, Ernst E. Hypericum for depression: an update of the clinical evidence. Eur Neuropsychopharmacol. 1999;9:501-505.
24. Maidment I. The use of St John's Wort in the treatment of depression. Psychiatric Bulletin. 2000;24:232-234.
25. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for 8 weeks. BMJ. 1999;319:1534-1538.
26. Woelk H. Comparison of St. John's Wort and imipramine for treating depression: randomised controlled trial. BMJ. 2000;321:536-539.
27. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) treatment of depression: a double-blind, randomized pilot study. Clin Ther. 2000;22:411-419.
28. Schrader E, Equivalence of St. John's Wort extract (Ze 117) and fluoxetine: randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61-68.
29. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry. 1997;154:1757-1759.
30. Landén M, Eriksson E, Ågren H, Fahlen T. Effect of bus-pirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19:268-271.
31. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-1109.
32. Druid H, Holmgren P. Dödsfall genom akut fluoxetinförgiftning. Lakartidningen. 1996;93:4149-4150.
33. Goh KT. Fatal overdose with citalopram. Lancet. 1996;348:339-340.
34. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. Johns Wort (Hypericum perforatum L.). Eur J Clin Pharmacol. 1998;54:589-594.
35. Stevinson C, Ernst E. Safety of hypericum in patients with depression. CNS Drugs. 1999;11:125-132.
36. Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John's Wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30(suppl 71):81-85.
37. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry. 1997;30:94-101.
38. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's Wort. Lancet. 1998;352:1121-1122.
39. Bon S, Hartmann K, Kuhn M. Johanneskraut ein Enzyminduktor? Schweitzer Apothekerzeitung. 1999;16:535-536.
40. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's Wort and theophylline. Ann Pharmacother. 1999;33:502.
41. Rey JM, Walter G. Hypericum perforatum (St. John's Wort) in depression: pest or blessing? Med J Aust. 1998;169:583-586.
42. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. Johns Wort: effect on CYP3A4 activity. Clin Pharmacol Ther. 2000;67:451-457.
43. Ernst E. Second thoughts about safety of St John's Wort. Lancet. 1999;354:2014-2016.
44. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's Wort. Lancet. 2000;355:547-548.
45. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to St John's Wort. Lancet. 2000;355:548-549.
46. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology. 1967;6:278-296.
47. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
48. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
49. Thornett A. Use of hypericum as antidepressant: valid measure of antidepressant efficacy in primary care is needed. BMJ. 2000;320:1141.
50. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's Wort. Biol Psychiatry. 1999;46:1707-1708.
51. Agency for Health Care Policy and Research. Treatment of Depression - Newer Pharmacotherapies: Summary, Evidence Report/Technology Assessment Number 7. Rockville, MD: Agency for Health Care Policy and Research; 1999.
52. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's Wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978-1986.
53. Fomous CM, Cardellina JH 2nd, Cohen HW. St. John's Wort and major depression. JAMA. 2001;286:42-45.
54. Bergman U, Isacsson G. Självmord och antidepressiva: finns det ett samband. Nordic Journal of Psychiatry. 1997;38:21-26.
55. Isacsson G, Bergman U. Ökad användning av antidepressiva: en utveckling i rätt riktning. Lakartidningen. 1997;94:1484-1486.
56. Argyropoulos SV, Nutt DJ. Substance P antagonists: novel agents in the treatment of depression. Expert Opinion on Investigational Drugs. 2000;9:1871-1875.